Comments
It will be a fortnight of litigation, with two cases filed with the Delhi High Court recently slated to come up for hearing. The case over fixed dose combination drugs comes up on May 5. A clutch of companies had gone to the court after the Health Ministry outlawed 344 combination drugs for being unsafe. The other case involves Roche’s biologic breast cancer drug Herceptin, which comes up for the next hearing on May 10. The court had issued an interim order stopping generic drugmakers Biocon, Mylan and Reliance Life Sciences from claiming they were making biosimilars (that is, a highly similar version of the innovator’s product.) of Herceptin. But that order was stayed pending Mylan’s appeal.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.